SCHEMBL3764667

SCHEMBL3764667

CCN(CC)C(=O)c1ccccc1-c1[c]nccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.49
HCRTR1 O43613 8/20 0.47
HCRTR2 O43614 8/20 0.47
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.44
ADRA1A P35348 2/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1B P35368 1/20 0.43
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.40
OPRD1 P41143 1/20 0.40
KCNH2 Q12809 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758756 0.84 MEN1 (0.54) KEAP1HCRTR1HCRTR2TP53MAPT
SCHEMBL3766045 0.80 ALDH1A1 (0.39) KEAP1HCRTR1HCRTR2TP53MAPT
SCHEMBL3761226 0.79 KDM4C (0.44) ALOX5APFEN1ALDH1A1
SCHEMBL3761435 0.77 TSHR (0.56) TP53MAPTTSHRALDH1A1ALOX15
SCHEMBL3759345 0.77 ALDH1A1 (0.45) MAPTTSHRNPC1ALDH1A1HPGD
SCHEMBL1200639 0.75 CSNK1A1 (0.51) KEAP1MAPTALOX5APFEN1TSHR
SCHEMBL3769034 0.75 GAA (0.45) ADRA1AADRA1DADRA1BALOX5APFEN1
SCHEMBL29822323 0.74 TP53 (0.69) KEAP1TP53MAPTADRA1AADRA1D
SCHEMBL610480 0.74 TP53 (0.69) KEAP1TP53MAPTADRA1AADRA1D
SCHEMBL3629780 0.73 MEN1 (0.66) KEAP1HCRTR1HCRTR2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KEAP1 657/4885HCRTR1 4187/4885HCRTR2 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.